November 8, 2024
TOPLINE: Venetoclax–obinutuzumab combination therapy for untreated chronic lymphocytic leukemia (CLL) shows a 6-year progression-free survival (PFS) rate of 53%. The time-to-next-treatment (TTNT) rate is 65%, with […]
November 7, 2024
TOPLINE: Patients treated for prostate cancer had higher rates of complications, including urinary and sexual issues, than a control group of men. Radiotherapy increases the risk […]
November 7, 2024
TOPLINE: The risk for breast induration is associated with the volume of irradiated breast tissue in patients aged 65 years or older, but not in those […]
November 6, 2024
When treating brain metastases in patients with non–small cell lung cancer (NSCLC), brain radiotherapy has been the standard option. However, a growing body of evidence indicates […]
November 6, 2024
Increasing the uptake of palliative care may decrease the aggressiveness of end-of-life care, an analysis of ovarian cancer decedents suggested. Palliative care initiated earlier than 3 […]
November 6, 2024
TOPLINE: In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings […]
November 5, 2024
Last month, the US Food and Drug Administration (FDA) approved three new drugs, as well as a potentially practice-changing cancer screening tool, and expanded indications for […]
November 4, 2024
TOPLINE: Long-term residential exposure to fine particulate matter, nitrogen dioxide, and black carbon are positively linked to lung cancer incidence and mortality, with similar risks found […]
November 4, 2024
TOPLINE: Patients with cancer who participated in the Medicare Low-Income Subsidy program were less likely to receive any systemic cancer therapy compared with patients not participating […]